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Abstract
Lyme disease is a rapidly growing illness that remains poorly understood within the medical community. Critical questions about when and
why patients respond to treatment or stay ill, what kinds of treatments are effective, and even how to properly diagnose the disease remain
largely unanswered. We investigate these questions by applying machine learning techniques to a large scale Lyme disease patient registry,
MyLymeData, developed by the nonprofit LymeDisease.org. We apply various machine learning methods in order to measure the effect of
individual features in predicting participants’ answers to the Global Rating of Change (GROC) survey questions that assess the self-reported
degree to which their condition improved, worsened, or remained unchanged following antibiotic treatment. We use basic linear regression,
support vector machines, neural networks, entropy-based decision tree models, and k-nearest neighbors approaches. We first analyze the
general performance of the model and then identify the most important features for predicting participant answers to GROC. After we identify
the “key” features, we separate them from the dataset and demonstrate the effectiveness of these features at identifying GROC. In doing so,
we highlight possible directions for future study both mathematically and clinically.
1 Introduction
Lyme disease is the most common vector-borne disease in the United
States. The CDC estimates that 300,000 people in the U.S. (approx-
imately 1% of the population) are diagnosed with Lyme Disease
each year [1], a rate 1.5 times higher than breast cancer [2], and six
times higher than HIV/AIDS [3].
In its early, or acute, form, the disease may cause a hallmark
erythema migrans (EM) rash and/or flu-like symptoms such as fever,
malaise, fatigue, and generalized achiness [4]. A significant pro-
portion of patients with Lyme disease develop chronic debilitating
symptoms that persist in the absence of initial treatment or following
short-course antibiotic therapy [5]. This condition is commonly re-
ferred to as post-treatment Lyme disease or as chronic or persistent
Lyme disease. In this paper, we refer to these patients as having
persistent Lyme disease.
It is estimated that as many as 36% of those diagnosed and treated
early remain ill after treatment [5]. However, despite the high
incidence and severity of Lyme disease, little research has been done,
both clinically and analytically [6–9]. The result has been a stagnant
and controversial research environment with little innovation and a
costly lack of understanding or consensus. Physicians still do not
know the best way to diagnose or treat Lyme, how it progresses, or
why some patients respond to treatment and others do not.
Motivating questions. We are motivated by questions that in-
terest both physicians and patients to better inform treatment ap-
proaches and to identify factors that might predict treatment re-
sponse.
MyLymeData. Founded over 30 years ago, LymeDisease.org
(LDo) is a national 501(c)(3) non-profit dedicated to advocacy, re-
search and education. LDo has conducted surveys with the Lyme
disease patient community since 2004, and published the results in
peer reviewed journals. In November 2015, LDo launched MyLy-
meData, a patient registry. MyLymeData has enrolled over 13,000
patients and continues to grow. Participants are asked hundreds of
questions regarding their health history, diagnosis, symptoms, and
treatment.
The first study using data from the registry was published in 2018.
That study focused on treatment response variation among patients
and identified a subgroup of high treatment responders using the
Global Rating of Change Scale (GROC), a widely used and highly
validated treatment response measurement [10]. The GROC survey
questions assess the degree to which participants reported that their
condition improved, worsened, or remained unchanged following
antibiotic treatment. We assign participants to class labels based
on their GROC responder status. We label each participant as
a high responder if they experienced substantial improvement, a
low responder if they experienced slight improvement, and a non-
responder if they worsened or remained unchanged. Medically, a
major goal is to understand what patient attributes, protocols, or
circumstances lead to patient improvement.
Machine learning techniques. One challenge facing medical
experts looking to derive insights from the data is that the high-
dimensional structure of the data obscures the relationship between
patient features and their GROC responder status. In this work,
we apply various machine learning models in order to measure
the efficacy of individual features (survey question responses) in
classifying the patients’ GROC responder status, and to identify both
meaningful and redundant information within the survey responses.
We apply both simple wrapper and filter approaches to feature
selection [11]. We aggregate the results of several approaches to
select a final subset of features we find most relevant to patients’
GROC responder status, thereby highlighting what patient attributes
and protocols are most likely associated with improved patient well
being. These findings point to areas where additional analysis might
prove useful.
Organization. In Section 2, we describe the MyLymeData
dataset and preprocessing steps, and introduce the techniques and
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models that we use throughout the paper. In Section 3.1, we run all
the models on the full MyLymeData dataset to evaluate the potential
of each model to predict GROC labels using all of the data features.
In Section 3.2, we apply the models to individual features to identify
the features that are most important in predicting GROC labels and
we form a subset of top features by aggregating the results of all
the models. In Section 3.3, we evaluate the predictive ability of
this subset of top features in comparison to the full dataset. Finally,
in Section 4 we discuss our results and their implication to Lyme
Disease treatment protocols.
2 Data and Methods
Here we describe our experimental setup, the MyLymeData set, and
the models and methods we use.
2.1 Experimental Setup
All experiments are run on a MacBook Pro 2015 with a 2.5 GHz
Intel Core i7 and a MacBook Pro 2018 with a 2.9 GHz Intel Core
i9. We use Matlab version R2019b and Python version 3.7.3 to run
experiments. We create linear regression models using Matlab’s
fitlm() function. We create neural networks models using Tensor-
flow; our network architecture is detailed in Section 2.4.3. We
run support vector machine (SVM), Decision Tree, and k-nearest
neighbors (KNN) models using the Python scikit-learn library. We
run the SVM using the sklearn.svm.SVC() function, we run the
Decision Tree with the sklearn.DecisionTreeClassifier() function
and criterion=“entropy” parameter, and we run the KNN model
with the sklearn.KNeighborsClassifier() function. We use default
hyperparameters for all functions, and experimentally choose opti-
mal values of max depth for decision trees and K value for KNN.
We directly calculate entropy in Section 3.2.3 for exact values.
2.2 The Dataset
We use data from Phase 1 of the MyLymeData patient registry.
Participants include respondents who report being US residents
diagnosed with Lyme disease. We look only at participants who
satisfy all of the following criteria:
1. Participant has persistent Lyme disease, which consists of
patients who have experienced persistent symptoms for at least
six months after antibiotic treatment.
2. Participant responded that they were unwell.
3. Participant answered the GROC (Global Rating of Change)
survey questions.
We assign each participant a label based on their response to
GROC, as previously described in [10]. As asked, the GROC ques-
tion produces a 17 point Likert scale. It is a two part question asking
first if the patient is "better", "worse", or "unchanged". Patients who
responded that they were better or worse are asked to specify the
degree of improvement ranging from "almost the same" to "a very
great deal better/worse". "Almost the same" responses for better or
worse were combined with the unchanged response. As modified,
the resultant 15 point Likert scale ranges between -7 and 7, with 0
as the midpoint for unchanged. We separate participants into three
categories:
1. Non-responders, who answered between -7 and 0, indicating
there was no improvement.
2. Low responders, who answered between 1 and 3, indicating
there was slight improvement.
3. High responders, who answered between 4 and 7, indicating
there was substantial improvement.
Our dataset consists of 2162 participants who satisfy the neces-
sary criteria and 215 features (question responses) drawn from the
MyLymeData survey. Each participant is assigned a label indicat-
ing non-responder, low responder, or high responder. The dataset
has a total of 947 non-responders, 396 low responders, and 819
high responders. The 215 features cover diagnostic factors (such
as delays to diagnosis, stage of diagnosis or presence of coinfec-
tions), treatment approach, individual antibiotic use and duration of
use, alternative treatments, symptoms (severity, presence at time of
diagnosis, and three worst), type of clinician, and degree of func-
tional impairment. We refer to this dataset as MLD (MyLymeData),
and we refer to all participants with a specific label as a class of
participants.
In order to improve the survey-taking experience for participants,
the format of the survey used a branching structure to direct only
relevant questions to participants. Thus, for many of the features in
our analysis only a subset of participants provided a response. For
every such feature, we group all participants who did not respond to
the feature together with a unique response.
For our figures, we provide abbreviations of the relevant features.
A name with a number following it indicates a series of questions
within the same subtopic, and here we note such features with
an “i”. “Bio_Sex” indicates biological sex. “Sx_Dx_i” indicate
symptoms present at diagnosis. “Tick” indicates the presence of a
tick bite. “Sx_Sev_i” indicate the severity of specific symptoms.
“Sx_Top_i” indicate a specific symptom as being in the top 3 symp-
toms. “Abx” indicates whether the participant is currently taking
antibiotics and/or alternative treatments. “Abx_Not_i” indicate the
reasons that a participant is current not taking antibiotics. “Abx_Dur”
indicates the duration of the current antibiotic treatment protocol.
“Abx_Eff” indicates the effectiveness of the current antibiotic treat-
ment protocal. “Abx_Oral,” “Abx_IM,” and “Abx_IV” indicate
whether the current antibiotic protocal includes oral, IM, and/or IV
antibiotics, respectively. “Abx_i” indicate whether the participant
is currently taking a specific oral antibiotic. “Abx_IM_i” indicate
whether the participant is current taking a specific IM antibiotic.
“Alt_Tx_Eff_i” and “Alt_Tx_Sfx_i” indicate the effectiveness of
and side effects of current alternative treatment approaches, respec-
tively. “Med_i” indicate whether a participant is taking a specific
non-antibiotic medication. “Provider_i” indicate whether a partici-
pant’s Lyme disease is being treated by a specific type of healthcare
provider. “Wrk_Day” indicates the number of times a participant
went to work but was unable to fully concentrate because of not
feeling well. These features are more fully described in Table 6 of
the Appendix.
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2.3 Techniques
Here we introduce the methods that we utilize through our experi-
ments to help us assess importance of the features in determining
participants’ GROC responder status.
2.3.1 Subsampling
Most of the machine learning techniques that we use require bal-
anced class sizes to produce accurate results. For this reason, we
subsample the the data by selecting participants from MLD so that
there are an even number of non-responders, low responders, and
high responders. Thus, this dataset has 396 participants with each
label. We refer to the subsampled dataset as SMLD (subsampled
MyLymeData). We will use a fixed subsample throughout the ex-
periments for consistency.
2.3.2 Permuting Labels
We wish to show that the models created from our datasets out-
perform the same models on similar, but random and meaningless
data. This is important because some models overfit even to random
data given an appropriate number of datapoints and features. We
compare our results on MLD to the results on similar but random
data. We create such a dataset by randomly permuting the labels
and reassociating them with participants. We perform this on both
MLD and SMLD and call these random datasets RMLD (random
MyLymeData) and RSMLD (random subsampled MyLymeData).
2.3.3 Dropping Features
One way we assess the contribution of each feature to the model’s
predictive ability is by evaluating the accuracy of a model with
the entire dataset, and then removing a feature from the dataset
and reevaluating the accuracy. Ideally, the most important features
would cause the largest decrease in accuracy when they are removed
from the dataset. This metric allows us to assess how influential
each feature is to the model.
2.3.4 Validation Function
For models that are prone to overfitting, we use a function that
effectively evaluates validation accuracy. This function accepts a
dataset and a classifier, and over a specified amount of trials (30
by default), creates a random 75/25 training and testing split of the
data that is different on every trial, fits the classifier to the training
data, and measures accuracy on the testing data. We will call this
function our validation function.
2.4 Models
Our machine learning methods are all supervised learning methods,
meaning that the model aims to learn a mapping from an input, in
this case our participants and their responses, to an output, in this
case the three classes we identified. We use two distinct supervised
learning methods, regression and classification. Regression mod-
els produce a continuous value that numerically approximates the
output, while classification models produce a discrete output, in
this case one of the three classes. In our classification models, we
calculate accuracy A as
A =
|Tc|
|T | (1)
where |T | denotes the total amount of participants and |Tc| denotes
the total amount of participants that were predicted correctly.
2.4.1 Linear Regression
Linear regression is a regression model that attempts to produce
the best affine hyperplane to fit a dataset. The model computes the
optimal affine hyperplane that minimizes the sum of the squares of
the distances of the points from their projections onto the hyperplane
along the dependent variable coordinate subspaces.
2.4.2 SVM
A support vector machine (SVM) is a popular and widely used
classification model in the area of machine learning. The model
attempts to separate datapoints of different classes with an affine
hyperplane. The SVM aims to find the optimal hyperplane by
reducing both the amount of points classified incorrectly and the
distance of these incorrectly classified points from the hyperplane.
To achieve our multiclass classification task, SVM separates the
three classes via three hyperplanes that attempt to separate each
class from the other classes. In our experiments using the SVM
model when dropping out features (see Section 2.3.3), we examine
the training accuracy to measure the separability of the dataset by
an affine hyperplane.
2.4.3 Neural Network
We train a neural network model with two dense layers. In Figure
1, we display the architecture of our neural network. Each hidden
layer has 20 nodes. We use a softmax output layer for multiclass
classification. We compile our model with an Adam optimizer [12].
x1
x2
...
x215
y1
y2
y3
Hidden
layer
Hidden
layer
Input
layer
Output
layer
Figure 1: Neural Network Architecture
We train each model for 50 epochs, train 30 models, and of these
30 models choose the model with the highest validation accuracy.
The neural network objective function is nonconvex so we do multi-
ple runs to avoid poor local minima. We then measure the accuracy
of our best model using additional test data. We repeat this entire
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process multiple times and average over the results to attain an
average test accuracy which we use to evaluate the effectiveness of
the model. This process is more complex than our other models,
but is valuable because of the nonlinearity and expressive capability
of the model. We also increase the train/test ratio to 0.8/0.2 for our
neural network to allow for sufficient training data.
Due to computational constraints, we do not run the neural net-
work when selecting top features, but only to evaluate general per-
formance and evaluate the effectiveness of the top features we select.
Because the neural network objective is nonconvex, there is varia-
tion in each run so we would need to run the neural network many
times to be able to find significant differences between features
which is computationally prohibitive.
2.4.4 Entropy and Decision Tree
In order to create the decision tree, we use the entropy metric to
measure the importance of each feature. The goal of entropy is
to calculate the randomness of the data, so we measure feature
importance by calculating the decrease in entropy after the data is
split by the feature. Let X be a discrete random variable that takes
on a value of one of the three labels with probability
pX(i) =
|Ti|
|T | (2)
where |T | denotes the total participants and |Ti| denotes the partici-
pants with label i. Then, We measure entropy as
H[X] = −E(log(X)) = −
∑
i
pX(i) log(pX(i)) (3)
Using this criterion, we measure the importance of a feature by
comparing the entropy of the dataset to the conditional entropy
of the dataset after the dataset is split based on the participants’
responses to this question. We refer to the decrease in entropy as
information gain.
We create a decision tree that assesses feature importance using
the entropy criterion. To create this tree, the scikit-learn model
places the most important features highest in the tree to improve its
ability to split the data based on class labels, so at every node the
function uses the feature that most effectively decreases entropy. In
order to prevent overfitting with the decision tree, we run our tree
model on the validation function as outlined in section 1.2.4, once
at every depth, and choose the depth that produces the maximum
validation accuracy.
2.4.5 k-Nearest Neighbors
The KNN algorithm classifies an example by looking at the k points
nearest to it and selecting the most common label amongst these
points. We measure the distance between points using Euclidean
distance. The most important decision when training this model is
the choice of k. We split our data into training data and validation
data, and we choose K by training our model on the training data
with various choices of k and choosing the value that produces the
maximum accuracy by the validation function as outlined in Section
2.3.4.
3 Results
First, we run each of our models on the complete dataset in order
to evaluate the potential of each model to predict GROC labels
using all of the data features. We then run our models on individual
features in order to identify features that are important in predicting
GROC labels, and we aggregate these results into a subset of “key"
features. Finally, we run our models on the two subsets of only
the key features and only the remaining features to measure the
effectiveness of our identified key feature set at predicting GROC
labels.
3.1 General Performance
We first run each of our models on our datasets to evaluate the po-
tential of each model to predict GROC labels using all of the data
features. This gives us a measure to compare against in determining
the importance of each feature in the next section. We also demon-
strate the inaccuracy of the model at predicting undersampled labels
in MLD which motivates subsampling the data.
In Table 5 we list the results of running each model on four
datasets: MLD, randomized MLD (RMLD), subsampled MLD
(SMLD), and randomized subsampled MLD (RSMLD) (details for
the construction of these datasets is provided in Sections 2.3.1 and
2.3.2). We list prediction accuracies for our classification models,
and relevant regression values for the linear regression model.
Table 1: Results for running each model on MLD, randomized MLD (RMLD),
subsampled MLD (SMLD), and random subsampled MLD (RMLD). For linear re-
gression we list regression values and for our classificaiton models we list accuracies
measured by the validation function (details in 2.3.4).
Model MLD RMLD SMLD RSMLD
SVM 0.576 0.400 0.484 0.342
Neural Net 0.598 0.422 0.518 0.325
Decision Tree 0.600 0.526 0.432 0.335
KNN 0.542 0.439 0.490 0.335
Linear Regression
R2 0.397 0.095 0.416 0.175
Adjusted R2 0.331 -0.004 0.290 -0.003
p-value 3.7E-108 0.439 6.2E-36 0.400
RMSE 0.738 0.904 0.688 0.818
We see that for classification on randomized MLD (RMLD), we
achieve above-random accuracies (significantly larger than 0.333),
which can be attributed to a a variation in class sizes, while the classi-
fication accuracies for randomized subsampled MLD (RSMLD) are
all approximately 0.333. This suggests that a part of the high accu-
racies reported for MLD in comparison to SMLD can be attributed
to factors unrelated to the predictive ability of the model.
In Tables 2 and 3, we display the accuracy of the MLD and SMLD
datasets at prediction for participants of each GROC class. We see
that for all of our models, the classification accuracies for MLD vary
significantly across GROC class, and that the low responders, the
class with the least participants, has very poor prediction accuracy.
For each of our models, this variation is significantly reduced for
classification on SMLD.
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Table 2: Prediction accuracies of each classification model on MLD for participants
of each GROC class (non-responders, low responders, high responders).
Model Non Low High
SVM 0.709 0.193 0.605
Neural Net 0.728 0.139 0.635
Decision Tree 0.776 0.107 0.636
KNN 0.691 0.033 0.613
Table 3: Prediction accuracies of each classification model on subsampled MLD
(SMLD) for participants of each GROC class (non-responders, low responders, high
responders).
Model Non Low High
SVM 0.546 0.383 0.522
Neural Net 0.487 0.465 0.606
Decision Tree 0.641 0.305 0.634
KNN 0.509 0.429 0.534
Abx_Eff
Abx_EffSx_Sev_1
Abx_EffSx_Sev_5
... ...
... ... ... ...
Figure 2: Decision tree built by the scikit-learn library for SMLD using the entropy
metric. The ellipses indicate the continuation of the tree for each direction. At each
step, the model selects the feature that causes the largest decrease in entropy for the
current subset of the full data to split the tree. Note that each split along the tree is a
binary split, so we can have multiple splits along Abx_Eff because it has more than
two possible responses.
These preliminary results suggest to us that evenly subsampling
our MLD dataset could lead to more accurate and meaningful results
despite the higher classification accuracy for MLD. For this reason,
for the remainder of our classification tasks we use SMLD. These
regression and classification results also suggest to us that there is
a substantial relationship between a participant’s GROC class and
certain survey responses. Our goal in the next section will be to
identify the specific features with the most significant relationship
to GROC class.
3.2 Identifying Key Features
Here, we run our models on individual features in order to identify
the features that are most important in predicting GROC labels. We
list notable results here and will highlight those features that are
ranked highly by several models.
3.2.1 Linear Regression
In Figure 3 we show the results of running linear regression on
SMLD and measuring the R2 values of the individual features; see
Section 2.1 for experimental design details. Here, we calculate R2
values by running a separate single-variable regression for each
feature.
Figure 3: R2 values of individual features on Subsampled MLD (SMLD). Here we
display the top 30 features by R2 value in descending order.
3.2.2 SVM
In Figure 4 we record the change in training accuracy of the SVM
on SMLD after dropping each feature from the data set individually;
see Section 2.1 for experimental design details and see Section
2.3.3 for details about the dropout process. In order to accurately
assess the effect of dropping each feature, we take random subsets
of SMLD and run the model on each subset of the data. Using
this method, we suggest that the magnitude of decrease in accuracy
when dropping a feature demonstrates its ability to predict GROC
value. For this reason, in Figure 4 we also sort the features in order
of decreasing accuracy drop.
One weakness of this metric is that small impacts to the shape of
the dataset from dropping out a feature can cause random changes to
testing accuracy that make our ranking less precise. To address this
we use training accuracy to measure the separability of the dataset.
5
Figure 4: SVM training accuracy dropping individual deatures on Subsampled MLD
(SMLD). For each feature, we measure the decrease in accuracy caused by removing
a single feature from the dataset. Here we display the top 30 features by accuracy in
descending order.
In Figure 5 we show the results of running the SVM model on
only individual features rather than dropping the feature from the
entire dataset.
Figure 5: SVM accuracy of individual featues on Subsampled MLD (SMLD). We
attain this accuracy by running our SVM model on only the single feature. Here we
display the top 30 features by accuracy in descending order. We measure accuracies
by the validation function (details in 2.3.4).
3.2.3 Entropy / Decision Tree
We measure the information gain produced by each feature by
calculating the difference of the original entropy of the features and
the conditional entropy after splitting the data into separate groups
based on the responses to this feature. For entropy calculations, we
do not use the subsampled data because the difference in class sizes
does not negatively affect performance as we are not performing a
classification task that could result in poor classification accuracy on
underrepresented labels. Meanwhile, the decision tree model, which
uses this entropy calculation for classification, does suffer from
uneven prediction results (e.g., a one node decision tree degenerates
to a majority classifier) so for classification we apply the model to
the subsampled dataset. In Figure 6 we list the top entropy gain
produced by individual features in MLD, sorted in descending order
of entropy gain.Âa˘
Figure 6: Information gain of individual features on MLD. Here we display the top
30 features by entropy in descending order. We measure accuracies by the validation
function (details in 2.3.4).
3.2.4 k-Nearest Neighbors
In Figure 7 we display the results of running the KNN model on
individual features; see Section 2.1 for experimental design details.
To do this, we train our model using only a single feature in place
of the entire data set. We can interpret this as projecting each data
point onto the axis of that feature, so the space we are learning
within is one dimensional. For each feature, we tune the model on a
small batch of possible k values.
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Figure 7: KNN accuracy of individual features on Subsampled MLD (SMLD).
Here we display the top 30 features by accuracy in descending order. We measure
accuracies by the validation function (details in 2.3.4).
3.2.5 Top Features
From the results of our models we now create a ranking of the most
important features in our dataset for predicting GROC labels. To do
this, we first define R(m, i) to be the ranking of feature i by model
m. Since we have 215 features, note that 1 ≤ R(m, i) ≤ 215 for all
i, m. For each the metric we use to produce the ranking is the metric
used to order the features in Figures 3, 4, 5, 6, and 7. In order to
aggregate these rankings, we take the simple approach of averaging
the ranking of each feature by all of our models. Let S (i) be the
average rank of feature i. Then
S (i) =
1
5
5∑
m=1
R(m, i).
This aggregates our rankings into a single score where smaller
values indicate more important features. In Table 4, we show the
top 30 features sorted by value.
Table 4: Top Feature Ranks
Feature Rank Feature Rank
Abx_Eff 1.2 Abx_IM_6 34.8
Sx_Sev_1 2.8 Abx_21 36
Sx_Sev_4 5 Sx_Sev_6 39.2
Sx_Sev_8 9.4 Abx_No_7 40
Sx_Sev_10 18.2 Abx_18 40.4
Abx_No_1 20.4 Abx_No_3 41.2
Sx_Sev_5 21.2 Abx_1 42
Abx_No_4 22.4 Sx_Sev_9 43.2
Abx_No_9 22.6 Sx_Sev_12 43.6
Abx_No_6 24.2 Abx_No_8 43.8
Sx_Sev_7 28.8 Provider 45.8
Abx_24 30.2 Abx_No_2 46
Abx_3 31.4 Abx_Sfx 46.8
Abx_No_5 32 Abx_IM 47.6
Abx_Dur 33.2 Abx_Oral 47.8
3.3 Restricting to Key Features
In order to demonstrate the significance of the top 30 features (dis-
played in Table 4) that we have identified through our previous
experiments as being important for predicting GROC labels, we run
experiments using a dataset with only these 30 features and a dataset
with all but these 30 features. We refer to the dataset of the 30 most
important features as TSMLD (top subsampled MyLymeData), and
we refer to the dataset of 185 remaining features as BSMLD (bottom
subsampled MyLymeData).
In Table 5 we list the results for running each model on subsam-
pled MLD (SMLD), top subsampled MLD (TSMLD), and bottom
subsampled MLD (BSMLD). We list prediction accuracies for our
classification models, and relevant regression values for the linear
regression model. See Section 2.1 for experimental design details.
Table 5: Results for running our models on subsampled MLD (SMLD), top subsam-
pled MLD (TSMLD), and bottom subsampled MLD (BSMLD). For linear regression
we list regression values and for our classificaiton models we list accuracies measured
by the validation function (details in 2.3.4).
Model SMLD TSMLD BSMLD
SVM 0.484 0.546 0.436
Neural Net 0.518 0.506 0.477
Decision Tree 0.523 0.528 0.426
KNN 0.490 0.519 0.441
Linear Regression
Adjusted R2 0.290 0.274 0.136
p-value 6.2E-36 6.8E-67 6.5E-12
By every metric, we see that the 30 features we identified (repre-
sented above by TSMLD) match or outperform the dataset of all 215
features (represented above by SMLD), suggesting that they hold a
significant portion of the information which yields each model their
predictive ability for the GROC label. These results also suggest
possible redundancy in the dataset given the the large portion of
features that contain a small amount of the information used by
the models for their predictive ability. The results could also offer
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intuition for LymeDisease.org, the creators of this survey, about
what features to focus on in designing future surveys, as well as
intuition for other future survey designers.
4 Discussion
Here we explore and analyze the results from the previous sections.
4.1 Predictive Significance of MyLymeData
Dataset
Our models were able to achieve a highest test accuracy of 0.613 on
MLD and 0.517 on SMLD using a neural network for predicting the
three classes of GROC response. We demonstrate that a significant
portion of the predictive information from the dataset comes from
only 30 of the 215 features. In fact, for many models our top dataset
of 30 features performed better than the full dataset.
4.2 Antibiotics
Of the 30 top features that we identified from the models, 20 of
these features related directly to antibiotics, which suggests that
many factors relating to antibiotics, including the effectiveness of
antibiotic treatment (Abx_Eff), the length of the current treatment
protocol (Abx_Dur), and the reasons why a participant is not taking
antibiotic (Abx_Not), are important predictors of a participant’s
GROC class.
By most of our models, Abx_Eff was the most important feature
by a large margin. This is expected because the effectiveness of
the current antibiotic treatment may reflect response to antibiotic
therapy generally, which GROC measures. This suggests a very
close relationship between antibiotic treatment and GROC label.
This also yields intuitive evidence that the models are successfully
selecting the most important features, since the information offered
by Abx_Eff should make it a top feature.
The fact that most of the features identified in the top 30 were
related to the use of antibiotic treatment is important because there
is currently an on-going debate about whether antibiotics are useful
for treating persistent Lyme disease. Our analysis suggests that
antibiotic related questions may be the most important in predicting
a patient’s treatment response for those with persistent Lyme dis-
ease. This topic is explored in greater detail in a companion study
analyzing the role of specific features identified in the top 30 in
connection with treatment response [13].
4.3 Symptoms
Of the top 30 features we identified from our models, nine of these
features are from the 13 named Sx_Sev_i that ask about the current
severity of specific symptoms, suggesting that these symptoms or the
severity of these symptoms are important predictors of GROC class.
Based on our ranking metric, the second most important predictor
of GROC label is feature Sx_Sev_1, which asks the current severity
of fatigue symptoms. To visualize this relationship, in Figure 8 we
provide a chart relating participants’ responses to Sx_Sev_1 with
GROC label.
Figure 8: (Top) A stacked bar graph with participants from each GROC class by their
answers to severity of fatigue symptoms (Sx_Sev_1), increasing in severity. (Bottom)
a normalized version of the bar graph that gives the percentage representation of
each GROC class by response to Sx_Sev_1, for better visualization of trends.
Figure 8 demonstrates a clear relationship between Fatigue sever-
ity and GROC treatment response label, as it shows that participants
who report no minimal, or mild symptom severity for fatigue are
most often high responders, while those with severe or very severe
fatigue are most often non-responders. This suggests that the sever-
ity of fatigue symptoms could be a useful metric in determining
GROC for Lyme disease patients, which matches this result in our
experiment.
4.4 Branching
Although feature Abx did not appear in our list of top 30 features,
a more comprehensive analysis reveals the true importance of this
feature. Feature Abx identifies whether the participant is taking
antibiotics, and this feature is used for branching purposes, so fea-
tures concerning specifics of antibiotic treatment are only asked to
patients who indicated in this feature that they are currently taking
antibiotics. Thus, any feature that relies on the branching effect of
Abx will inherently contain all the information contained in Abx,
since for any such feature all patients who are not taking antibiotics
would be grouped together. For this reason, Abx does not serve
the purpose that the top 30 features list represents; our intention
was to find 30 features that effectively predict GROC labels, and
since other features in this list that result from the branching of Abx
contain all the relevant information about whether a patient is taking
antibiotics, Abx would not increase the predictive ability of models
run on this set and or offer unique information. We can see this
represented in our analysis; Abx had an average rank of 31 amongst
all metrics other than SVM drop-out, in which it ranked 191 0f
215. Since the SVM drop-out was the only metric that measured a
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feature by examining the loss from removing it, these results can
be explained by the lack of unique information offered by Abx as
explained above while also demonstrating the importance of Abx
independent of the rest of the dataset.
The branching structure also affects the importance and inter-
pretability of the top feature set by yielding some features with
substantial predictive information unrelated to the purpose of the
question being asked. Within the top feature set, those that appear
to be most affected by this are the Abx_i features and Abx_IM_6.
Upon further inspection, these features have little significance aside
from maintaining the branching information from Abx that identi-
fies which participants are currently taking antibiotics, yet the little
information they add after this split make them more important than
Abx based on information content alone. On one hand, this indicates
that the subject matter of these features may not be as important as
the analysis initially suggests. Yet, this does not take away from
the purpose of these features within the top features list, which is to
hold as much significant information as possible in a small subset
of the features, since these features do hold important information
from the branching in Abx.
4.5 Machine Learning for Survey Data
Here we outline two important factors one should consider when
applying machine learning methods to a survey dataset.
One consideration comes in choosing the models and metrics of
evaluation. Within the goal of finding important features in a data
set, one can either evaluate the predictive information from a single
feature, or remove a single feature from the data set and measure
the effects on performance, as in an abalation study. The former
metric measures the predictive information from a single feature,
while the later metric measures the amount of information unique
to the specific features in comparison to the other features. Of our
five metrics for measuring importance of individual features used
in our analysis, four measure features independantly of the data set,
and one, the SVM dropout metric, removed a feature from the data
set to measure performance. Our results align with this intuition of
the metrics; we explored this distinction of metrics in the previous
section in the context of feature Abx.
When applying machine learning models to survey data for fea-
ture selection, it is also important to contextualize the data and
results within the branching structure, which can affect the meaning
and interpretation of the results. We describe the effects of the
branching structure on our analysis in the previous section.
5 Conclusion
We provide results of applying various simple feature selection tech-
niques to the LDo MLD dataset. These techniques provide insights
to which participant features are most important in determining
participant GROC responder status. These insights may be valuable
to medical professionals in determining the factors that are most
predictive of treatment response.
Furthermore, these results demonstrate the potential and efficacy
of these simple feature selection techniques for determining impor-
tant aspects of datasets. We expect that similar experiments could
be valuable in survey development, for survey design and reduction
of survey fatigue, as well as in other areas of science.
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Appendix
Table 6: Descriptions of relevant features. This includes all features mentioned in the paper. The Feature Name is the name used throughout the paper and the Variable
Name is the original name used by the MyLymeData dataset.
Feature Name Variable Name Description
Abx U1000 Current treatment approach (antibiotics/alternative/both/neither)
Abx_Dur U1020 Current antibiotic treatment duration
Abx_Eff U1040 Effectiveness of current antibiotic treatment
Abx_i U1120_i Specific oral antibiotic currently taking
Abx_IM U1100_2 Current antibiotic protocol includes IM antibiotics
Abx_IM_i U1690_i Specific intramuscular antibiotics currently taken
Abx_IV U1100_3 Current antibiotic protocol includes IV antibiotics
Abx_Not_i U1010_i Reason currently not taking antibiotics
Abx_Oral U1100_1 Current antibiotic protocol includes oral antibiotics
Abx_Sfx U1060 Level of negative side effects of current antibiotic protocol
Alt_Tx_Eff_i U2100_i1 Effectiveness of alternative treatment approaches
Alt_Tx_Sfx_i U2100_i2 Level of side effects of alternative treatment approaches
Bio_Sex R200 Biological sex
Curr_med_i U2150_i Other current medications
Provider_i U3000_i Type of healthcare provider that currently treats my lyme disease
Sx_Dx_i B390_i Symptoms at diagnosis
Sx_Sev_i U80_i Symptom severity
Sx_Top_5 U90_5 Top 3 worst symptoms
Tick B270 Recollection of tick bite prior to onset of symptoms
Wrk_Day U3150_2 Presenteeism (unable to concentrate at work)
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